OncoMatch/Clinical Trials/NCT05683886
A Study of KC1036 in Patients with Advanced Thymic Tumors
Is NCT05683886 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies KC1036 for thymic tumors.
Treatment: KC1036 — This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage IV (Masaoka-Koga)
advanced recurrent, unresectable and/or metastatic thymic tumor as defined by the Masaoka-Koga stage
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic chemotherapy — first-line
Subsequent relapse of disease following first-line systemic chemotherapy
Cannot have received: small molecule VEGFR-TKI
Exception: patients whose treatment cycle is less than 2 weeks due to intolerance or other reasons
Patients who have previous treatment with small molecule VEGFR-TKI (except patients whose treatment cycle is less than 2 weeks due to intolerance or other reasons)
Cannot have received: PD-1/PD-L1 antibody combined with small molecule VEGFR-TKI
Patients who have previous treatment with PD-1 / PD-L1 antibody combined with small molecule VEGFR-TKI
Cannot have received: chemotherapy
Exception: within 4 weeks before enrollment; palliative radiotherapy excepted
Prior anti-tumor therapies with chemotherapy, cytotherapy, immunotherapy, operation (Interventional therapy excepted) within 4 weeks before enrollment; Prior radiotherapy (palliative radiotherapy excepted) within 2 weeks; Prior small-molecule targeted therapy within 2 weeks or 5 half-lives
Cannot have received: cytotherapy
Exception: within 4 weeks before enrollment
Prior anti-tumor therapies with chemotherapy, cytotherapy, immunotherapy, operation (Interventional therapy excepted) within 4 weeks before enrollment
Cannot have received: immunotherapy
Exception: within 4 weeks before enrollment
Prior anti-tumor therapies with chemotherapy, cytotherapy, immunotherapy, operation (Interventional therapy excepted) within 4 weeks before enrollment
Cannot have received: operation
Exception: within 4 weeks before enrollment; Interventional therapy excepted
Prior anti-tumor therapies with chemotherapy, cytotherapy, immunotherapy, operation (Interventional therapy excepted) within 4 weeks before enrollment
Cannot have received: radiotherapy
Exception: within 2 weeks before enrollment; palliative radiotherapy excepted
Prior radiotherapy (palliative radiotherapy excepted) within 2 weeks
Cannot have received: small-molecule targeted therapy
Exception: within 2 weeks or 5 half-lives before enrollment
Prior small-molecule targeted therapy within 2 weeks or 5 half-lives
Lab requirements
Blood counts
adequate organ and marrow function
Kidney function
adequate organ and marrow function
Liver function
adequate organ and marrow function
Adequate organ and marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify